SLS (SELLAS Life Sciences Group, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by SLS officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-18 | Angelos M. Stergiou | President and CEO | A | — | — |
| 2026-01-09 | DRAGAN CICIC | SVP, Chief Development Officer | A | — | — |
| 2026-01-09 | John Varian | Director | A | — | — |
| 2026-01-09 | John Thomas Burns | CFO | A | — | — |
| 2026-01-09 | Jane Wasman | Director | A | — | — |
| 2026-01-09 | DAVID A SCHEINBERG | Director | A | — | — |
| 2026-01-09 | Katherine Bach Kalin | Director | A | — | — |
| 2026-01-09 | ROBERT L VAN NOSTRAND | Director | A | — | — |
| 2025-12-05 | Angelos M. Stergiou | President and CEO | J | — | — |
| 2025-12-05 | DRAGAN CICIC | SVP, Chief Development Officer | J | — | — |
| 2025-12-05 | John Thomas Burns | CFO | J | — | — |
| 2025-11-21 | Katherine Bach Kalin | Director | Buy | — | — |
| 2025-06-13 | ROBERT L VAN NOSTRAND | Director | Buy | — | — |
| 2025-06-02 | Jane Wasman | Director | Buy | — | — |
| 2025-05-22 | Katherine Bach Kalin | Director | Buy | — | — |
| 2025-01-14 | DAVID A SCHEINBERG | Director | A | — | — |
| 2025-01-14 | John Varian | Director | A | — | — |
| 2025-01-14 | Angelos M. Stergiou | President and CEO | A | — | — |
| 2025-01-14 | Jane Wasman | Director | A | — | — |
| 2025-01-14 | ROBERT L VAN NOSTRAND | Director | A | — | — |
| 2025-01-14 | Katherine Bach Kalin | Director | A | — | — |
| 2025-01-14 | John Thomas Burns | CFO | A | — | — |
| 2025-01-14 | DRAGAN CICIC | SVP, Chief Development Officer | A | — | — |
| 2024-12-05 | DRAGAN CICIC | SVP, Chief Development Officer | J | — | — |
| 2024-12-05 | Angelos M. Stergiou | President and CEO | J | — | — |
| 2024-12-05 | John Thomas Burns | CFO | J | — | — |
| 2024-01-25 | Angelos M. Stergiou | President and CEO | A | — | — |
| 2024-01-25 | ROBERT L VAN NOSTRAND | Director | A | — | — |
| 2024-01-25 | John Thomas Burns | CFO | A | — | — |
| 2024-01-25 | BARBARA A WOOD | EVP, Gen. Counsel, Corp. Sec. | A | — | — |
| 2024-01-25 | Katherine Bach Kalin | Director | A | — | — |
| 2024-01-25 | Jane Wasman | Director | A | — | — |
| 2024-01-25 | DAVID A SCHEINBERG | Director | A | — | — |
| 2024-01-25 | John Varian | Director | A | — | — |
| 2024-01-25 | Robert Francomano | Chief Commercial Officer | A | — | — |
| 2023-12-08 | Robert Francomano | Chief Commercial Officer | J | — | — |
| 2023-12-08 | John Thomas Burns | CFO | J | — | — |
| 2023-12-08 | Angelos M. Stergiou | President and CEO | J | — | — |
| 2023-12-08 | BARBARA A WOOD | EVP, Gen. Counsel, Corp. Sec. | J | — | — |
| 2023-02-03 | ROBERT L VAN NOSTRAND | Director | A | — | — |
| 2023-02-03 | Jane Wasman | Director | A | — | — |
| 2023-02-03 | Angelos M. Stergiou | President and CEO | A | — | — |
| 2023-02-03 | DAVID A SCHEINBERG | Director | A | — | — |
| 2023-02-03 | John Varian | Director | A | — | — |
| 2023-02-03 | Katherine Bach Kalin | Director | A | — | — |
| 2023-02-03 | John Thomas Burns | CFO | A | — | — |
| 2023-02-03 | Robert Francomano | Chief Commercial Officer | A | — | — |
| 2023-02-03 | BARBARA A WOOD | EVP, Gen. Counsel, Corp. Sec. | A | — | — |
| 2022-12-05 | John Thomas Burns | Senior VP, Finance & CAO | Sell | — | — |
| 2022-12-05 | Angelos M. Stergiou | President and CEO | Sell | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | President and CEO | 1,759,183 | — |
| — | SVP, Chief Development Officer | 557,805 | — |
| — | CFO | 554,327 | — |
| — | Director | 154,400 | — |
| — | EVP, Gen. Counsel, Corp. Sec. | 117,225 | — |
| — | Director | 92,900 | — |
| — | Director | 82,900 | — |
| — | Director | 73,082 | — |
| — | Director | 72,900 | — |
| — | Chief Commercial Officer | 40,918 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the SLS quote page; the site-wide leaderboard is on the insider transactions hub.